Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray
Go back to Acadia Pharma (ACAD): 2Q Results Don't Capture A Real Indication For NUPLAZID Demand - Piper Jaffray| Acadia Pharmaceuticals, Inc. (NASDAQ: ACAD) | Delayed: 16.96 -0.03 (0.18%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $16.99 | 52 Week High | $42.49 | |||
| Open | $17.09 | 52 Week Low | $16.64 | |||
| Day High | $17.24 | P/E | N/A | |||
| Day Low | $16.88 | EPS | $-0.42 | |||
| Volume | 129,330 | |||||
